Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976303 | 0.92 | LTA4H (0.57) | KDM4EALDH1A1SMN1; SMN2HRH3SIGMAR1 | |
| SCHEMBL15260249 | 0.87 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HRH3ACHE | |
| SCHEMBL29615450 | 0.82 | HRH3 (0.54) | KDM4EHRH3ACHERAD52L3MBTL1 | |
| SCHEMBL22918759 | 0.82 | HRH3 (0.54) | KDM4EHRH3ACHERAD52L3MBTL1 | |
| SCHEMBL15260226 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7564110 | 0.77 | KDM4E (0.82) | KDM4EALDH1A1SMN1; SMN2HRH3ACHE | |
| SCHEMBL21004113 | 0.76 | HRH3 (0.84) | HRH3ACHERAD52MEN1KMT2A | |
| SCHEMBL21004213 | 0.75 | KDM4E (0.65) | KDM4EALDH1A1SMN1; SMN2HRH3ACHE | |
| SCHEMBL3581930 | 0.75 | HRH3 (0.89) | HRH3ACHERAD52L3MBTL1 | |
| SCHEMBL28285426 | 0.74 | HRH3 (0.88) | HRH3ACHERAD52MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315761-B1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LTD (GB) | 2018-07-11 | — | — | EP | disclosed |
| EP-2315761-B1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LTD (GB) | 2018-07-11 | — | — | EP | disclosed |
| US-8461339-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461339-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461339-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| EP-2315761-A1 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010007374-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007374-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | NR2C2, NR3C2, NR0B2 | KDM4E 3351/4885ALDH1A1 4706/4885SMN1; SMN2 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.